E7389 + E7389 + E7389
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Trial Timeline
Oct 1, 2011 → May 1, 2015
NCT ID
NCT01418677About E7389 + E7389 + E7389
E7389 + E7389 + E7389 is a phase 1 stage product being developed by Eisai for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT01418677. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01418677 | Phase 1 | Completed |
| NCT00706095 | Phase 1 | Completed |
Competing Products
20 competing products in Unspecified Adult Solid Tumor, Protocol Specific
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| bevacizumab + enzastaurin hydrochloride | Eli Lilly | Phase 1 | 33 |
| SHR-1916 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| PI3K inhibitor BKM120 + docetaxel | Novartis | Phase 1 | 33 |
| bevacizumab + cyclophosphamide + imatinib | Novartis | Phase 1 | 33 |
| capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | Novartis | Phase 1 | 33 |
| warfarin | Novartis | Phase 1 | 33 |
| RLY-1971 | Roche | Phase 1 | 33 |
| Domvanalimab + Zimberelimab | Gilead Sciences | Phase 1 | 32 |
| BEZ235 + MEK162 | Pfizer | Phase 1 | 32 |
| Utomilumab + ISA101b | Pfizer | Phase 2 | 51 |
| Irinotecan | Pfizer | Phase 1 | 32 |
| Ixabepilone + Sunitinib | Pfizer | Phase 1 | 32 |
| ixabepilone + lapatinib ditosylate | Bristol Myers Squibb | Phase 1 | 32 |
| carboplatin + irinotecan hydrochloride | Bristol Myers Squibb | Phase 1 | 32 |
| intoplicine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| Sorafenib | Bayer | Phase 2 | 49 |